Literature DB >> 27443648

Chemotherapy-Related Neurotoxicity.

Sophie Taillibert1, Emilie Le Rhun2,3,4, Marc C Chamberlain5.   

Abstract

Chemotherapy may have detrimental effects on either the central or peripheral nervous system. Central nervous system neurotoxicity resulting from chemotherapy manifests as a wide range of clinical syndromes including acute, subacute, and chronic encephalopathies, posterior reversible encephalopathy, acute cerebellar dysfunction, chronic cognitive impairment, myelopathy, meningitis, and neurovascular syndromes. These clinical entities vary by causative agent, degree of severity, evolution, and timing of occurrence. In the peripheral nervous system, chemotherapy-induced peripheral neuropathy (CIPN) and myopathy are the two main complications of chemotherapy. CIPN is the most common complication, and the majority manifest as a dose-dependent length-dependent sensory axonopathy. In severe cases of CIPN, the dose of chemotherapy is reduced, the administration delayed, or the treatment discontinued. Few treatments are available for CIPN and based on meta-analysis, duloxetine is the preferred symptomatic treatment. Myopathy due to corticosteroid use is the most frequent cause of muscle disorders in patients with cancer.

Entities:  

Keywords:  Chemobrain; Chemotherapy; Chemotherapy-induced peripheral neuropathy; Encephalopathy; Myopathy; Neurotoxicity

Mesh:

Year:  2016        PMID: 27443648     DOI: 10.1007/s11910-016-0686-x

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  110 in total

1.  Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.

Authors:  A Lintermans; B Van Calster; M Van Hoydonck; S Pans; J Verhaeghe; R Westhovens; N L Henry; H Wildiers; R Paridaens; A S Dieudonné; K Leunen; L Morales; K Verschueren; D Timmerman; L De Smet; I Vergote; M R Christiaens; P Neven
Journal:  Ann Oncol       Date:  2011-01-27       Impact factor: 32.976

2.  Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.

Authors:  Linda Mileshkin; Richard Stark; Bruce Day; John F Seymour; Jerome B Zeldis; H Miles Prince
Journal:  J Clin Oncol       Date:  2006-08-28       Impact factor: 44.544

3.  Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings.

Authors:  Jennifer E Fugate; Daniel O Claassen; Harry J Cloft; David F Kallmes; Osman S Kozak; Alejandro A Rabinstein
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

Review 4.  Venlafaxine for neuropathic pain in adults.

Authors:  Helen C Gallagher; Ruth M Gallagher; Michelle Butler; Donal J Buggy; Martin C Henman
Journal:  Cochrane Database Syst Rev       Date:  2015-08-23

5.  Longitudinal assessment of chemotherapy-induced alterations in brain activation during multitasking and its relation with cognitive complaints.

Authors:  Sabine Deprez; Mathieu Vandenbulcke; Ronald Peeters; Louise Emsell; Ann Smeets; Marie-Rose Christiaens; Frederic Amant; Stefan Sunaert
Journal:  J Clin Oncol       Date:  2014-05-27       Impact factor: 44.544

6.  Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients.

Authors:  Fahed Zairi; Emilie Le Rhun; Nicolas Bertrand; Thomas Boulanger; Sophie Taillibert; Rabih Aboukais; Richard Assaker; Marc C Chamberlain
Journal:  J Neurooncol       Date:  2015-06-13       Impact factor: 4.130

7.  Ifosfamide associated myoclonus-encephalopathy syndrome.

Authors:  Rodolfo Savica; Alejandro A Rabinstein; Keith A Josephs
Journal:  J Neurol       Date:  2011-03-12       Impact factor: 4.849

Review 8.  Nervous system infections in patients with cancer.

Authors:  Amy A Pruitt
Journal:  Neurol Clin       Date:  2003-02       Impact factor: 3.806

Review 9.  Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy.

Authors:  Louise Nott; Timothy J Price; Ken Pittman; Kevin Patterson; Janice Fletcher
Journal:  Leuk Lymphoma       Date:  2007-09

Review 10.  Systematic review of topical amitriptyline for the treatment of neuropathic pain.

Authors:  D F Thompson; K G Brooks
Journal:  J Clin Pharm Ther       Date:  2015-06-07       Impact factor: 2.512

View more
  26 in total

1.  Effect of an Internet-based telehealth system on functional capacity and cognition in breast cancer survivors: a secondary analysis of a randomized controlled trial.

Authors:  Noelia Galiano-Castillo; Manuel Arroyo-Morales; Mario Lozano-Lozano; Carolina Fernández-Lao; Lydia Martín-Martín; Rosario Del-Moral-Ávila; Irene Cantarero-Villanueva
Journal:  Support Care Cancer       Date:  2017-06-22       Impact factor: 3.603

2.  A Scientific Rationale to Improve Resistance Training Prescription in Exercise Oncology.

Authors:  Ciaran M Fairman; Michael C Zourdos; Eric R Helms; Brian C Focht
Journal:  Sports Med       Date:  2017-08       Impact factor: 11.136

3.  Chemotherapy-Induced Neuropathy in Cancer Survivors.

Authors:  Christine Miaskowski; Judy Mastick; Steven M Paul; Kimberly Topp; Betty Smoot; Gary Abrams; Lee-May Chen; Kord M Kober; Yvette P Conley; Margaret Chesney; Kay Bolla; Grace Mausisa; Melissa Mazor; Melisa Wong; Mark Schumacher; Jon D Levine
Journal:  J Pain Symptom Manage       Date:  2017-01-04       Impact factor: 3.612

4.  Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy.

Authors:  Paul Lennart Vollmers; Christoph Mundhenke; Nicolai Maass; Dirk Bauerschlag; Stefan Kratzenstein; Christoph Röcken; Thorsten Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-25       Impact factor: 4.553

5.  Changes in cognition and dendritic complexity following intrathecal methotrexate and cytarabine treatment in a juvenile murine model.

Authors:  Tyler C Alexander; Christy M Simecka; Frederico Kiffer; Thomas Groves; Julie Anderson; Hannah Carr; Jing Wang; Gwendolyn Carter; Antiño R Allen
Journal:  Behav Brain Res       Date:  2017-12-08       Impact factor: 3.332

6.  Axonal Degeneration Is Mediated by Necroptosis Activation.

Authors:  Macarena S Arrázola; Cristian Saquel; Romina J Catalán; Sebastián A Barrientos; Diego E Hernandez; Nicolás W Martínez; Alejandra Catenaccio; Felipe A Court
Journal:  J Neurosci       Date:  2019-03-08       Impact factor: 6.167

Review 7.  Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity.

Authors:  Pooja Gupta; Tavneet Kaur Makkar; Lavisha Goel; Monika Pahuja
Journal:  Immunol Res       Date:  2022-07-20       Impact factor: 4.505

Review 8.  Visual Pathway Degeneration in Chemotherapy-Related Neurotoxicity: A Review and Directions for Future Research.

Authors:  David E Anderson; Sarah A Holstein; Sachin Kedar
Journal:  Neuroophthalmology       Date:  2020-01-06

Review 9.  Restriction of drug transport by the tumor environment.

Authors:  Rajender Nandigama; Berin Upcin; Bertal H Aktas; Süleyman Ergün; Erik Henke
Journal:  Histochem Cell Biol       Date:  2018-10-25       Impact factor: 4.304

10.  Case of neuromyelitis optica: bilateral sensorineural hearing loss and transverse myelopathy following intrathecal chemotherapy.

Authors:  Sergio A Castillo-Torres; Carlos A Soto-Rincón; Héctor J Villarreal-Montemayor; Beatriz Chávez-Luévanos
Journal:  BMJ Case Rep       Date:  2020-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.